Cytochrome P450 pharmacogenetics as a pr
β
Kazuki Takada; Million Arefayene; Zeruesenay Desta; Cheryl H. Yarboro; Dimitrios
π
Article
π
2004
π
John Wiley and Sons
π
English
β 133 KB
## Abstract ## Objective Pulse cyclophosphamide is the treatment of choice for severe lupus nephritis. However, not all patients respond to this therapy, and gonadal toxicity is of particular concern. Cyclophosphamide is a prodrug that requires activation by cytochrome P450 (CYP) enzymes. We condu